Drug Trial Radar · NCT07710703
NWRD09 for Persistent Cervical HPV16 Infection
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Nov 30, 2026
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Newish Biotech (Wuxi) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 45 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo controlled study to determine the efficacy and safety of NWRD09 in adult women with persistent cervical HPV16 infection.
Conditions
- Persistent Cervical HPV16 Infection
Interventions
NWRD09/ Placebo administered by IM injectionBiological
NWRD09/ Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with virologically-proven clearance of HPV 16 at week 16.Time frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.